BCL2L1 and neoplasm: Further improvements using structure-based design generated A-1331852 with further increased affinity for BCL-XL [76,77] and importantly oral bioavailability, affording it potent anti-tumour activity in haematological and solid tumour mouse models as a single agent, or in combination with chemotherapy.